A4 Conference Brochure - ISPNO 2016ispno2016.co.uk/.../01/Final-ISPNO-Conference-Programme.pdf42 International Symposium on Pediatric Neuro-Oncology 2016 Conference Programme MONDAY,

International Symposium on Pediatric Neuro-Oncology 201642

Conference Programme

MONDAY, 13 JUNE, 2016 Room

8:00 8:30 OPENING CEREMONY AND WELCOME - Professor Barry Pizer, Scientific Chair Hall 1 - A,B,C

8:30 - 10:00 CONCURRENT

Sponsored by Telethon Adventurers

MEDULLOBLASTOMA: MOLECULAR SESSION CHAIRS: Steve Clifford, Scott Pomeroy

Hall 1 - A,B,C

8:30 8:55 Invited Speaker: Medulloblastomics revisited: defining the driver genes & developmental origins of medulloblastoma subtypes

Paul Northcott

8:55 9:05 MB-82 The transcriptional landscape of medulloblastoma: Group 3 and Group 4 tumours comprise a single clinically significant expression continuum

Daniel Williamson

9:05 9:15 MB-87 Integrated genomics reveals novel subtypes of medulloblastoma subgroups Vijay Ramaswamy

9:15 9:25 MB-32 Medulloblastoma genotype dictates blood brain barrier phenotype Deanna Patmore

9:25 9:35 MB-16 Notch1 promotes group 3 medulloblastoma metastasis, initiation and self-renewal Suzana Assad Kahn

9:35 9:45 MB-102 Hematogenous dissemination of medulloblastoma drives leptomeningeal disease Livia Garcia

9:45 9:55 MB-103 DiSCoVERing innovative therapies: Combining genetically accurate disease models of medulloblastoma with advanced in silico analysis to identify novel therapeutic targets

Allison Hanaford

9:55 10:00 Discussion

10:00 10:30 COFFEE, EXHIBITION AND POSTER VIEWING Hall 2

10:30 - 12:00 MEDULLOBLASTOMA: CLINICAL SESSION CHAIRS: Amar Gajjar, Stefan Rutkowski

Hall 1 - A,B,C

Sponsored by Telethon Adventurers

10:30 10:50 MB-109 Preliminary results of COG ACNS0331: A phase III trial of Involved Field Radiotherapy (IFRT) and Low Dose Craniospinal Irradiation (LD-CSI) with chemotherapy in average risk medulloblastoma: A report from the Children’s Oncology Group

Jeff Michalski

10:50 11:00 MB-63 Subgroup-directed stratification of risk in infant medulloblastoma Debbie Hicks

11:00 11:10 MB-33 Clinical characteristics of patients with germline SUFU Mutations Léa Guerrini Rousseau

11:30 11:40 MB-89 Treatment failure in young children with desmoplastic medulloblastoma (DMB)/medulloblastoma with extensive nodularity (MBEN) treated according to the HIT protocols

Nicholas Gerber

11:10 11:20 MB-14 Molecular and prognostic heterogeneity within MYC and MYCN amplified medulloblastomas

Janet Lindsey

11:20 11:30 MB-49 Intensive treatment of high-risk medulloblastoma (HR-MB): how to learn from toxicities in an European setting of radiotherapists and physicists of the SIOP Brain Tumor Working Group

Lorenza Gandola

11:40 12:00 Discussion - Amar Gajjar

12:00 - 13:00 ROUND TABLE Hall 1 - A,B,C

Sponsored by Roche Do we need a new strategy for the introduction of new drugs in childhood brain tumours?

SESSION CHAIRS: Roger Packer, Darren Hargrave

12:00 12:05 Introduction Roger Packer, Darren Hargrave

12:05 12:20 An Oncologist’s Perspective Mark Kieran

12:20 12:35 The Industry Perspective Hubert Caron


13:00 14:00 LUNCH, EXHIBITION AND POSTER VIEWING Hall 2

www.ispno2016.com 43




NEUROSURGERY - ADVANCES IN NEUROSURGERY AND IMAGING IN PAEDIATRIC NEURO-ONCOLOGY

Room 3 A+B

8:30 8:35 Welcome and Introduction Conor Mallucci

Brain Stem and Spinal Cord Surgery - State of the Art Techniques MODERATORS: Charlie Teo Benedetta Pettorini

8:35 8:50 Neuromonitoring Overview Francesco Sala

8:50 9:05 Sydney Experience Charlie Teo

9:00 9:15 New York Experience Jeffrey Wisoff

9:15 9:25 NS-01 Pediatric intraoperative neurophysiological monitoring in posterior fossa surgery Andrea Carai

9:25 10:00 Round Table Debate: Should monitoring be a standard of care in brainstem and spinal cord surgery? Participating: Benedetta Pettorini, Francesco Sala, Charlie Teo, Jeffrey Wisoff, Richard Edwards

Case for: Richard Edwards. Case against: Charlie Teo

Room 3 A+B

10:00 10:30 COFFEE AND EXHIBITION Hall 2

10:30 - 13:00 Novel/Advanced Techniques for Brain Tumours MODERATORS:Kristian Aquilina Michael Handler

Room 3 A+B

10:30 10:45 Intra-operative MRI Conor Mallucci

10:45 11:00 Corticography for tumours/mapping for brain tumour surgery Frederick Boop

11:00 11:15 Endoscopic resection of brain tumors Giuseppe Cinalli

11:15 11:25 NS-10 Dominant hemispheric endoscopic surgery for third ventricular brain tumors Mark Souweidane

11:25 11:35 NS-11 Low-field PoleStar N20 mobile iMR system as an adjunct for pediatric brain tumor resection: feasibility, usefulness and safety

Jose Antonio Salinas Sanz

11:35 11:45 NS-29 Laser interstitial thermal ablation of pediatric CNS lesions: Initial experience in the intraoperative MRI suite

Alexander Petronio

11:45 12:30 Round Table: Should intra-operative MRI be a standard of care? Participating: Conor Mallucci, Stephanie Puget, Giuseppe Cinalli, Frederick Boop Case for: Frederick Boop. Case against: Stephanie Puget

12:30 12:40 NS-26 The role of surgery in non-NF-associated pediatric optic pathway gliomas (OPG) - Is there a new paradigm?

Laura-Nanna Lohkamp

12:40 12:50 NS-17 A phase 1 safety and imaging study of BLZ-100 in pediatric brain tumors Sarah Leary

12:50 13:00 NS-08 A flexible step design infusion catheter for prolonged drug delivery into the brain stem of children

Mark Souweidane

13:00 14:00 Lunch, Exhibition and Poster Viewing Hall 2

13:00 - 14:00 LUNCH SYMPOSIUM: Drug Delivery for Brain Tumours SESSION CHAIR: Richard Edwards

Room 12

Sponsored by Renishaw

Convection enhanced drug delivery to the brain: Potential impact in neuro-oncology Richard Edwards

Preclinical development of a translatable drug delivery platform Will Singleton

NS-21 Multi-catheter intermittent convection-enhanced delivery of carboplatin as a treatment for diffuse intrinsic pontine glioma (DIPG): pre-clinical rationale and early clinical experience

Richard Edwards





Sponsored by Cure ATRT Now and the Dana Farber Cancer Institute

ATRT SESSION CHAIRS: Susan Chi, Dan Williamson, Michael Frühwald

Hall 1 - A,B,C

14:00 14:25 Invited Speaker: Update on atypical teratoid/rhabdoid tumors: simple genomes but maybe not such a simple disease

Marcel Kool

14:25 14:35 AT-07 PLK1 as a therapeutic target in ATRT Irina Alimova

14:35 14:45 AT-09 Treatment of atypical teratoid rhabdoid tumors (ATRT) of the central nervous system with surgery, intensive chemotherapy, and 3-D conformal radiation (ACNS0333). A report from the Children’s Oncology Group

Alyssa Reddy

14:45 14:55 AT-13 The EU-RHAB experience: clinical, genetic and survival data define a standard of care and are the basis for clinical trials

Michael Frühwald

14:55 15:05 AT-18 Investigating the biology of atypical teratoid/rhabdoid tumors by whole genome CRISPR/Cas9 screening

Matthew P. Selby

15:05 15:15 AT-21 Integrated (epi)genomic analyses identify sub-group specific therapeutic targets in CNS rhabdoid tumors

Brian Golbourn

15:15 15:30 Discussion: Franck Bourdeaut


Sponsored by Philips IMAGING IN CNS TUMORS SESSION CHAIRS: Shivaram Avula, Andrew Peet, Zoltan Patay

Room 3 A+B

14:00 14:20 Invited Speaker: Pediatric brain tumor imaging: New concepts Zoltan Patay

14:20 14:30 RA-06 Characterization of tumor grade and extent using magnetic resonance fingerprinting: initial results

Peter de Blank

14:30 14:40 RA-07 Feasibility of early postoperative 18F-FET PET/MRI after surgery for brain tumor in pediatric patients

Lisbeth Marner

14:40 14:50 RA-11 Added value of 1-H magnetic resonance spectroscopy for the diagnosis of paediatric brain lesions in clinical practice

Karen Manias

14:50 15:00 RA-10 Subtle findings on spinal MRIs in children newly diagnosed with medulloblastoma Ute Bartels

15:00 15:10 RA-13 Comparison of final intra-operative MR scan and post-operative MRI performed 24 to 72 hours after brain tumour resection

Shivaram Avula

15:10 15:30 Invited Speaker: The challenges of diagnosis and quantification tumour progression Tim Jaspan

15:30 16:00 Coffee and Exhibition Hall 2

15:30 16:00 Medtronic Presentation Room 3 A+B

16:00 - 17:30 PLENARY

Sponsored by the Amy Laura Fund

CEREBELLAR MUTISM SYNDROME SESSION CHAIRS:Marianne Juhler, David Walker, Jeremy Schmahmann

Hall 1 - A,B,C

16:00 16:05 Introduction Marianne Juhler

16:05 16:10 Film David Walker

16:10 16:20 Establishing a consensus on Cerebellar Mutism Syndrome in children after tumour surgery

Thora Gudrunardottir

16:20 16:30 Cerebellar Cognitive Affective Syndrome (CCAS) / Posterior Fossa Syndrome (PFS)in adults and children

Jeremy Schmahmann

16:30 16:40 Surgical strategies to minimise risk Robert Keating

16:40 16:50 CMS-06 The NOPHO-European study on cerebellar mutism syndrome (CMS) Morten Wibroe

16:50 17:00 CMS-07 Long term follow up with DTI fiber tractography of cerebro-cerebellar pathways and clinical evaluation of ataxia in childhood posterior fossa tumor survivors

Ulrich W. Thomale

17:00 17:10 CMS-08 Neuropsychological functioning in children with medulloblastoma: The impact of cerebellar mutism within the first year following diagnosis

Karin Walsh




17:30 - 19:00 POSTER SESSION 1 SESSION CHAIRS:John HeathKatherine Warren

Hall 2

Sponsored by the National Brain Tumor Society

19:30 SOCIAL EVENTS

Cavern Club

Alma de Cuba

TUESDAY, 14 JUNE, 2016 Room

7:00 - 8:30 Breakfast Meetings

Sponsored by Roche 1. Molecular Based Diagnosis: David Jones, Tim Jacques Room 4A

Sponsored by Childhood Brain Tumour Foundation

2. The Evolution of Brain Tumour Surgery: Charlie Teo, Michael Handler Room 4B


CNS TUMOURS IN LOW AND MIDDLE INCOME COUNTRIES SESSION CHAIRS: Simon Bailey, Eric Bouffet, Raman Arora

Hall 1C

8:30 8:50 Invited Speaker: Treating brain tumours in low and middle income countries: Closing the gap

Alan Davidson

8:50 9:00 LMI-01 Development of clinical guidelines for the treatment of low grade gliomas in lower and lower middle income countries – A SIOP PODC initiative

Laila Hessissen

9:00 9:10 LMI-04 Chemotherapy-only strategies for young children newly-diagnosed with malignant brain tumors: Can they be applied successfully in developing countries? The Malaysian Experience

Jonathan Finlay

9:10 9:20 LMI-14 Practical implementation of 3-D radiotherapy training in Africa with a focus on paediatric neuro-oncology

Jeannette Parkes

9:20 9:30 LMI-17 Centralized pathology review as a reliable option to achieve better outcome of patients with central nervous system (CNS) tumours in a low income country

Sidnei Epelman

9:30 9:40 EPI-08 Epidemiology of pediatric primary CNS tumors in Jordan, 2001-2010 Nisreen Amayiri

9:40 10:00 Discussion: Simon Bailey, Eric Bouffet, Raman Arora


CRANIOPHARYNGIOMA AND RARE TUMOURS SESSION CHAIRS: Benedetta Pettorini, Tom Merchant, Ute Bartels

Hall 1 A+B

8:30 8:55 Invited Speaker: Adamantinomatous Craniopharyngioma: lessons from mouse models

JP Martinez-Barbera

8:55 9:05 CR-11 Pediatric adamantinomatous craniopharyngioma cyst fluid demonstrates a pro-inflammatory milieu

Todd C. Hankinson

9:05 9:15 CR-16 Expression analysis of adamantinomatous craniopharyngioma reveals networks of co-expressed gene networks associated with different cellular compartments

John Apps

9:15 9:25 CR-06 Hydrocephalus and hypothalamic involvement in pediatric patients with craniopharyngioma or cysts of Rathke’s pouch: Impact on long-term prognosis

Hermann L. Müller

9:25 9:35 CR-10 Online survey on the management of paediatric craniopharyngiomas Benedetta Pettorini

9:35 9:45 CR-12 Intracystic interferon-alpha in paediatric craniopharyngioma patients: an international multi-centre assessment on behalf of SIOP-E and ISPN

John-Paul Kilday

9:45 10:00 WRAP UP: Ute Bartels

10:00 10:30 Coffee and Exhibition Hall 2





Sponsored by the PLGA Foundation

LOW GRADE GLIOMA SESSION CHAIRS: Mark Kieran, Netteke van Schouten, Stefan Pfister

Hall 1 A,B

10:30 10:55 Invited Speaker: LGG post-NGS: a growing smorgasbord of molecular subentities David Jones

10:55 11:05 LG-02 MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism

Pratiti Bandopadhayay

11:05 11:15 LG-25 Pediatric low-grade gliomas with CRAF gene fusions respond differentially to targeted therapeutics based on dimerization profiles

Payal Jain

11:15 11:25 LG-26 Germline and somatic FGFR1 abnormalities in dysembryoplastic neuroepithelial tumors

Barbara Rivera

11:25 11:35 LG-47 Type II RAF Inhibitors inhibit BRAF mutations and truncated fusions in pediatric low-grade gliomas

Karen Wright

11:35 11:45 LG-46 Inferior outcome and poor response to conventional therapies in pediatric low-grade gliomas harboring the BRAF V600E mutation

Alvaro Lassaletta

11:45 11:55 LG-65 Clinicopathological features and outcome in adolescents/young adults (AYA) with low grade glioma (LGG) compared with children: a report from the Children’s Oncology Group

Ashley Margol

11:55 12:05 LG-61 Developing risk-based selection criteria for the next SIOP trial of “sight-saving therapy” for children with NF1-associated optic pathway glioma (NF1-OPG) - A multi-disciplinary consensus workshop

David Walker

12:05 12:30 Discussion: Mark Kieran


Sponsored by The Brain Tumour Charity

NURSING PROFESSIONALS SESSION CHAIRS: Monica Campbell, Faith Gibson

Hall 1C

10:30 10:35 Welcome and Introduction Helen Paisley

10:35 10:40 Brain Tumour Charity Introduction Sarah Lindsell

10:40 11:10 Precision Medicine in Paediatric Neuro-Oncology: Reality or Hype? Darren Hargrave

11:10 11:25 NU-10 Care and management of patient receiving novel targeted agents Tambra Dahlheimer

11:25 11:40 NU-05 Nursing education strategies for targeted therapy adverse effects Andrea Polito

11:40 11:55 NU-20 Antidepressant usage in pediatric brain tumor patients Anna Evans, Jennifer Madden

11:55 12:10 NU-07 Neuro-oncology ongoing support pathway; enhancing the process of rehabilitation, discharge and return to education and family life for children and young people diagnosed with a brain tumour

Louise Robinson

12:10 12:25 NU-17 The development of a brain tumour school passport for school children Helen Paisley

12:25 12:30 Wrap Up

12:30 - 13:00 PLENARY SESSION

Sponsored by the PLGA Foundation

The WHO classification update 2016 – what’s new for pediatric tumors? KEYNOTE SPEAKER: David Ellison

Hall 1 A,B

13:00 14:00 LUNCH, EXHIBITION AND POSTER VIEWING Hall 2

13:00 - 14:00 THE CURE STARTS NOW RESEARCH COMPETITIONShortlisted candidates:1. MRI Guided Focused Ultrasound: Targeted Drug Delivery in DIPG, Dr Saira Alli and Dr James Rutka2. Oncolytic Adenoviruses for the Treatment of DIPG, Dr Marta Alonso3. Dissecting Mutated Gene-Enhancer Networks in Pediatric Brain Cancers, Dr Lukas Chavez4. Oncolytic Virotherapy - Enhanced Cellular Immunotherapy, Dr Kellie Haworth5. A Trojan Horse Strategy Against DIPG, Dr Maria Tsoli

Room 4B

Sponsored by The Cure Starts Now Foundation





Sponsored by Roche HIGH GRADE GLIOMA SESSION CHAIRS: Chris Jones, Nada JabadoMatthias Karajannis

Hall 1 A,B

14:00 14:20 Invited Speaker: Inter- and intra- tumoral heterogeneity in HGG and DIPG Chris Jones

14:20 14:30 HG-53 Hypermutation and neoantigen formation predict response to immune checkpoint inhibition in childhood biallelic mismatch repair deficient glioblastoma

Uri Tabori

14:30 14:40 HG-110 Single-cell transcriptome analysis in pediatric hemispheric and midline high-grade gliomas

Mariella G. Filbin

14:40 14:50 HG-123 An epigenomic screen reveals the chromatin remodeling protein BPTF as a driver of high-grade glioma and diffuse intrinsic pontine glioma growth in vitro and in vivo

Adam Green

14:50 15:00 HG-108 Multispecific chimeric antigen receptor (CAR) T-cells overcome inter-patient tumor heterogeneity and exhibit enhanced antitumor functionality in the treatment of glioblastoma

Kevin Bielamowicz

15:00 15:10 HG-35 MET-PET delineates non-contrast enhancing tumor (nCET) regions at high risk for recurrence in pediatric high grade glioma

John T. Lucas, Jr.

15:10 15:20 TB-14 The INFORM personalized medicine study - new molecular insights into relapsed pediatric brain tumors

Barbara C. Worst

15:20 15:30 HG-128 BO25041 - A phase II open-label, randomized, multi centre comparative study of bevacizumab based therapy in paediatric patients with newly diagnosed supratentorial, infratentorial cerebellar, or peduncular high grade glioma

Jacques Grill



NURSING PROFESSIONALS SESSION CHAIRS: Dawn WilliamsJennifer Madden

Hall 1C

14:00 14:30 Proton Beam Therapy for Paediatric Brain Tumours: The Whys and Wherefores Nicky Thorp

14:30 14:45 NU-11 Proton pearls: Nursing clinical care management for proton beam radiation Corrine Hoeppner

14:45 15:00 NU-04 Development after pediatric brain tumor - a longitudinal study Ingrid Tonning Olsson

15:00 15:15 NU-15 Introduction of a quality of life program into neuro-oncology clinic at a busy academic center

Anna Evans

15:15 15:30 NU-08 What happened to me? A group for children to explore their brain tumour journey Jane Cope



CHARITY MEETING Room 4A

15:30 16:00 COFFEE AND EXHIBITION





Sponsored by the Cure Starts Now Foundation

DIPG SESSION CHAIRS:Dannis van Vuurden, Suzanne Baker, David Ziegler

Hall 1 A,B

16:00 16:10 HG-116 Oncogenic activity of histone mutations in the mammalian brain Jon Larson

16:10 16:20 HG-72 DIPG cells escape the pons early during tumour evolution Mara Vinci

16:20 16:30 HG-20 Combination of epigenetic modifiers CBL0137 and panobinostat is highly potent in vitro and in vivo for diffuse intrinsic pontine glioma

Maria Tsoli

16:30 16:40 HG-15 Targeting histone mutations in pediatric high grade gliomas David Daniels

16:40 16:50 HG-02 A phase 1/2 trial of the antibody Pidilizumab (MDV9300) in pediatric diffuse intrinsic pontine glioma

Iris Fried

16:50 17:00 HG-75 Clinical, radiological, and histo-genetic characteristics of long-term survivors of diffuse intrinsic pontine glioma: a collaborative report from the International and SIOP-E DIPG Registries

Lindsey Hoffman

17:00 17:10 HG-28 Survival benefit for patients with diffuse intrinsic pontine glioma (DIPG) undergoing re-irradiation at first progression: analysis of the SIOP-E-DIPG/HGG working group

Geert O. Janssens

17:10 17:25 Summary of session Dannis van Vuurden



NURSING PROFESSIONALS SESSION CHAIRS: Helen PaisleChristine Chordas

Hall 1C

16:00 16:30 What the research tells us about transition Faith Gibson

16:30 16:50 Moving Towards 2018 and Global Networking Jennifer Madden,Christine Chordas

16:50 17:00 Close and Handover to ISPNO 2018 Denver Helen Paisley

17:00 18:00 Nursing network event at PanAm at Albert Dock Sponsored by the Brain Tumour Charity



CHARITY MEETING Room 4A

17:30 - 18:30 POSTER SESSION 2 SESSION CHAIRS:Antony Michalski, Yoon Jae Cho

Hall 2

Sponsored byChildren with Cancer

19:15 CONFERENCE DINNER Hall 2

fighting the UK’s biggest child killer



WEDNESDAY, 15 JUNE, 2016 Room

7:00 8:30 Breakfast Meetings


1. Outcome Measures in Children with Neuropsychological impairements: Colin Kennedy, Stephen Sands

Room 4A

Sponsored by the Childhood Brain Tumour Foudation

2. Proton Beam Therapy: Tom Merchant, Andrew Chang Room 4B


Sponsored by Cure Brain Cancer Foundation

CNS PNET SESSION CHAIRS: Nick GottardoKatja von HoffMarcel Kool

Hall 1 A, B

8:30 8:50 Invited Speaker: CNS-PNETs- towards consensus Annie Huang

8:50 9:05 PNR-21 Four new brain tumor entities emerge from molecular classification of CNS-PNETs Marcel Kool

9:05 9:15 PNR-08 Newly discovered oncogenes driving and maintaining choroid plexus carcinoma provide potentially druggable targets

Birgit Nimmervoll

9:15 9:25 PNR-12 Genome-wide profiling of embryonal tumors with multilayered rosettes (ETMR) Sander Lambo

9:25 9:35 PNR-23 Shh and Wnt signalling are upregulated in human intraocular medulloepithelioma and lead to retinal tumor-like lesions in the mouse

Julia Dietlmeier

9:35 9:45 PNR-33 Molecular re-evaluation of institutionally diagnosed CNS-PNETs: clinical consequences of confined diagnostic groups

Katja von Hoff

9:45 9:55 PNR-39 Distinct gene fusions segregate sub-classes of CNS-PNETs Joseph Norman

9:55 10:00 Discussion: Katja von Hoff



QUALITY OF SURVIVAL SESSION CHAIRS:Mathilde Chevignard, Colin Kennedy, Donald Mabbott

Room 3

8:30 9:00 Invited Speaker: Multi-professional follow-up programmes are needed to address psychosocial, neurocognitive and educational issues in children treated for brain tumours

Ingrid Van’t Hoof

9:00 9:10 RO-21 A prospective assessment of HRQoL outcomes in medulloblastoma patients treated with proton radiotherapy (PT)

Torunn I. Yock

9:10 9:20 QOS-06 Repairing the brain with physical exercise: An exercise trial in pediatric brain tumor survivors. Insights from cortical thickness analysis and deformation based morphometry

Kamila Szulc

9:20 9:30 QOS-17 Questionnaire-based reports of Quality of Survival (QoS) and direct assessments of cognitive performance in children treated for medulloblastoma in the PNET 4 randomized controlled trial

Mathilde Chevignard

9:40 9:50 QOS-37 Validation of a parent- and self-report cognitive function questionnaire as a routine assessment of cognitive dysfunction

Martha Grootenhuis

9:30 9:40 QOS-30 Functional independence in adult survivors of pediatric CNS tumors: A report from the St. Jude Lifetime Cohort Study

Tara Brinkman

9:50 10:00 QOS-49 Impaired linguistic abilities and cortical re-mapping of the language processing in long-term posterior fossa tumour survivors

Olha Hodgson

10:00 10:30 Coffee and Exhibition





Sponsored by the CERN Foundation

EPENDYMOMA SESSION CHAIRS: Nicholas Foreman, Hendrik Witt, Michael Taylor

Hall 1 A, B

10:30 10:55 Invited Speaker: Leveraging advances in ependymoma biology to Inform clinical trials

Steven Mack

10:55 11:10 EPN-31 Molecular refinement of pediatric posterior fossa ependymoma Kristian W. Pajtler

11:10 11:20 EPN-12 Pediatric supratentorial ependymoma: comparison between immunohistochemistry, FISH and DNA methylation analysis for RELA rearrangement and histological correlation

Felipe Andreiuolo

11:20 11:30 EPN-34 Epigenomic analysis of ependymal tumors identifies subgroup specific enhancers controlling distinct regulatory circuitries

Lucas Chavez

11:30 11:40 EPN-24 Epigenetic silencing of LDOC1 leads to chronic IL-6 secretion through upregulation of NF-kB pathway in Group A Ependymoma: Potential for tailored therapies

Andrea Griesinger

11:40 11:50 EPN-30 YAP1-MAMLD1 fusions alone are sufficient to form supratentorial ependymoma-like tumors in mice

Kristian W. Pajtler

11:50 12:00 EPN-20 Newly diagnosed metastatic intracranial ependymoma in children: frequency, treatment and outcome in the population based, prospective HIT-series

Martin Benesch

12:00 12:10 EPN-14 Pediatric ependymoma: multi-institutional experience reveals poor long-term overall survival despite favorable five-year outcomes

Amanda Marinoff

12:10 12:20 RO-23 Recurrent ependymoma a challenging therapy: re-irradiation prolongs survival in failure of radical resection

Stephan Tippelt

12:20 12:30 Discussion: Nicholas Foreman


Sponsored by Roche PRE-CLINICAL MODELS SESSION CHAIRS: Rob Wechsler-ReyaOren Becher

Room 3

10:30 10:45 Invited Speaker: Patient-derived and autopsy-derived orthotopic xenograft (PDOX and ADOX) mouse models of childhood brain tumors

Holly Lindsay

10:45 10:55 PCM-16 Molecular characterization of orthotopic patient-derived xenograft models of pediatric brain tumors

Sebastian Brabetz

10:55 11:10 PCM-15 Somatic CRISPR/Cas9-mediated tumor suppressor disruption enables versatile brain tumor modeling

Marc Zuckermann

11:10 11:20 LG-27 DKFZ-BT66 - a novel pilocytic astrocytoma model for preclinical drug testing Florian Selt

11:20 11:30 PCM-19 The role of MEK-inhibitors for the prevention of optic pathway gliomas in an Nf1-deficient mouse model

Miriam Bornhorst

11:30 11:40 PCM-06 Accurate preclinical trials of new ependymoma therapies Karen Wright

11:40 11:50 PCM-17 Intratumoural convection enhanced delivery of LBH589 (panobinostat) loaded pluronic-P407 nano-micelles is associated with enhanced survival and anti-tumour response in the orthotopic F98/Fischer 344 rat glioma model

William GB Singleton

11:50 12:00 EPT-12 Targeting telomeres to treat therapy-resistant pediatric brain tumors Satarupa Sengupta

12:00 12:10 PCM-20 Pre-clinical drug screen in a PDX ETMR mouse model Christin Schmidt

12:10 12:30 Discussion: Rob Wechsler-Reya, Oren Becher


Sponsored by the Pediatric Brain Tumor Foundation

Imaging Tumour Metabolism KEYNOTE SPEAKER: Kevin Brindle,

Hall 1 A, B

13:00 14:00 LUNCH AND EXHIBITION Hall 2





Sponsored by the Robert Connor Dawes Foundation

Ependymoma and Beyond KEYNOTE SPEAKER:Richard Gilbertson

Hall 1 A, B


Sponsored by IRONMATT The Matthew Larson Foundation

GERM CELL TUMOURS SESSION CHAIRS: James NicholsonJonathan FinlayRyo Nishikawa

Hall 1 A, B

14:30 14:55 Invited Speaker: Biology of intracranial germ cell tumors Ching Lau

14:55 15:05 GC-03 Areas of non-consensus challenging the management of intracranial germ cell tumours (ICGCT)

Matthew Murray

15:05 15:15 GC-06 Management for relapsed intracranial malignant germ cell tumours James Nicholson

15:15 15:25 GC-08 Treatment and outcome of pediatric non-midline central nervous system germinoma: Children’s Hospital Los Angeles experience

Kee Kiat Yeo

15:25 15:35 GC-09 Genome-wide DNA methylation and transcriptomic profiling in primary central nervous system germ cell tumors suggests a primordial germ cell origin for germinoma

Koichi Ichimura

15:35 15:45 GC-10 A proposed pathway towards non-invasive microRNA-based diagnosis and risk stratification of CNS malignant germ cell tumours

Matthew Murray

15:45 16:00 Discussion: James Nicholson


Sponsored by Children with Cancer

EARLY PHASE STUDIES, DRUG DELIVERY SESSION CHAIRS: Darren HargraveGiles Robinson

Room 3

14:30 14:40 EPT-13 RAPIRI I – Phase I study of daily oral rapamycin and intravenous irinotecan in children with a recurrent/refractory malignant solid tumor: good tolerance and promising results in brain tumors - a report from the Société Française des Cancers et leucémies de l’Enfant et de l’adolescent (SFCE)

Natacha Entz-Werlé

14:40 14:50 EPT-01 Dose-finding study of vinblastine in combination with nilotinib in children, adolescents and young adults with refractory or recurrent low-grade glioma: Results of the ITCC/SIOPE-Brain VINILO phase I trial (NCT01887522)

Jacques Grill

14:50 15:00 EPT-08 A phase I study of single-agent perifosine for recurrent/refractory pediatric CNS and solid tumors

Nathan Millard

15:00 15:10 EPT-11 The potential role of regadenoson to transiently disrupt the blood-brain barrier and improve temozolomide delivery to brain tumors

Sadhana Jackson

15:10 15:20 EPT-14 Phase I study of gene mediated cytotoxic immunotherapy with AdV-tk as adjuvant to surgery and radiation therapy for pediatric malignant glioma and recurrent ependymoma

Mark W. Kieran

15:20 15:30 EPT-15 A phase1/2 clinical trial of veliparib (ABT-888) and radiation followed by maintenance therapy with veliparib and temozolomide (TMZ) in patients with newly diagnosed diffuse intrinsic pontine glioma (DIPG): a Pediatric Brain Tumor Consortium interim report of phase II study

Patricia Baxter

15:30 15:40 EPT-16 A Phase 1 trial of lenalidomide plus radiotherapy in children with newly diagnosed diffuse intrinsic pontine gliomas or high-grade gliomas

Kathy Warren

15:40 15:50 EPT-19 Phase I trial of Palbociclib, a CDK4/6 inhibitor in children with Retinoblastoma protein (Rb1) + recurrent central nervous system (CNS) tumors (PBTC 042)

Sridharan Gururangan

15:50 16:00 EPT-20 Clinical targeted exome-based sequencing in combination with genome wide copy number profiling: A CLIA certified approach for precision medicine in 203 pediatric brain tumor patients

Pratiti Bandopadhayay

16:00 16:05 CLOSING REMARKS Hall 1 A, B

fighting the UK’s biggest child killer

Documents

A4 Conference Brochure - ISPNO 2016ispno2016.co.uk/.../01/Final-ISPNO-Conference-Programme.pdf42 International Symposium on Pediatric Neuro-Oncology 2016 Conference Programme MONDAY,